Nextech Venture, located in Zurich, Switzerland, manages and advises two investment funds with a focus on healthcare. Nextech Venture’s Fund I is an early-stage venture fund focussing on European early-stage healthcare and information technology companies. With its unique oncology focused Fund II, Nextech Venture has become the world’s first dedicated investor for leading oncology companies in USA, Europe and Asia. Nextech Venture profits from the support of an active and committed Scientific Advisory Board of highly connected and influential scientific oncology advisors.
Nextech Venture organizes the Global Oncology Venture Event which is held annually in major cities around the globe.
Nextech Venture is independent from any other institution, be it financial, industrial or private. Is a member of the European Private Equity and Venture Capital Association EVCA and the Swiss Private Equity & Corporate Finance Association SECA.
| Company | Date | Round | Size | Participants |
| TetraLogic Pharmaceuticals | 5/11 | Series C | $6M | 1 |
| Sunesis Pharmaceuticals | 4/09 | Unattributed | $43.5M | 9 |
| Agensys | 7/07 | Series D | $41.3M | 8 |
